Summary. Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies.

Earnings Call Insights: Verona Pharma (VRNA) Q1 2025 Management View CEO David Zaccardelli highlighted the continued success of the Ohtuvayre launch for COPD maintenance treatment, with net ...

Summary. Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ...

Piper Sandler raised the firm’s price target on Verona Pharma (VRNA) to $160 from $76 and keeps an Overweight rating on the shares. Verona Pharma remains one of Piper’s top 2025 picks, where Street ...

Verona, has ginned up strong numbers for its first launch. Of the $42 million in sales, $36 million came in the fourth quarter. Ohtuvayre was prescribed by 3,500 different healthcare professionals ...

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights. Verona Pharma plc . Tue, Jan 7, 2025, 6:00 AM 7 min read.

Verona Pharma reports $36.6 million in Ohtuvayre sales for Q4 2024, with ongoing Phase 2 trials advancing. Quiver AI Summary. Verona Pharma plc announced its financial results for the fourth ...

Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment.

Verona plans to launch Ohtuvayre in the third quarter of this year. The date will be significant as Regeneron and Sanofi are expected to land a highly anticipated approval for Dupixent to treat ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Verona’s Ohtuvayre combines two mechanisms of action in a single drug. In addition to blocking PDE-4 to counteract inflammation, the drug blocks PDE-3 enzymes.